Clonazepam is NOT Recommended for PTSD
Clonazepam is ineffective for treating PTSD and should be avoided in this patient population. The American Academy of Sleep Medicine explicitly states that clonazepam is not recommended for nightmare disorder, and the 2024 VA/DoD guidelines recommend against benzodiazepines in PTSD management 1, 2.
Evidence Against Clonazepam in PTSD
Lack of Efficacy
The evidence base for clonazepam in PTSD is sparse and negative:
A randomized, single-blind, placebo-controlled crossover trial in 6 veterans with combat-related PTSD found clonazepam (1-2 mg at bedtime) was largely ineffective for sleep disturbances 3, 1, 4. There were no improvements in nightmare frequency (1.42 vs 1.33 with placebo) or intensity (2.15 vs 2.06 with placebo).
The AASM position paper explicitly lists clonazepam among medications "not recommended for the treatment of nightmare disorder" based on this limited evidence 1.
Significant Safety Concerns
Benzodiazepines, including clonazepam, carry substantial risks in PTSD patients that outweigh any potential benefits:
Increased suicide risk: A 2020 study of 5,753 PTSD patients found clonazepam was associated with significantly MORE suicide-related behaviors compared to alprazolam (p=0.0351) and showed trends toward increased risk compared to other benzodiazepines 5.
Worse PTSD outcomes: A systematic review and meta-analysis of 5,236 participants found benzodiazepines are associated with worse overall PTSD severity, significantly increased risk of developing PTSD when used after recent trauma, worse psychotherapy outcomes, aggression, depression, and substance use 6.
Prevention failure: A prospective study showed that early benzodiazepine administration (including clonazepam) to trauma survivors did NOT prevent PTSD development—in fact, 9 of 13 benzodiazepine-treated patients developed PTSD at 6 months versus only 3 of 13 controls 7.
Additional Adverse Effects
Sexual dysfunction: In male veterans with PTSD, 42.9% (18/42) taking clonazepam reported significant sexual dysfunction, primarily erectile dysfunction, at a mean dose of 3.4 mg/day—a rate not seen with other benzodiazepines 8.
Standard benzodiazepine risks: The FDA label warns of respiratory depression, dependence, withdrawal seizures, paradoxical reactions (agitation, nightmares, hallucinations), cognitive impairment, and abuse potential 9.
What to Use Instead
First-Line Treatments
For PTSD core symptoms:
- Trauma-focused psychotherapy (prolonged exposure, cognitive processing therapy, or EMDR) is recommended over pharmacotherapy 2
- SSRIs/SNRIs: Paroxetine, sertraline, fluoxetine, or venlafaxine 2, 10
For PTSD-related nightmares specifically:
- Image Rehearsal Therapy (Level A recommendation) 3, 1
- Prazosin (Level A recommendation for PTSD-associated nightmares): Start 1 mg at bedtime, titrate by 1-2 mg every few days to effective dose (typically 3-13 mg/day) 3
Common Pitfall
Clinicians often prescribe benzodiazepines for symptomatic relief of anxiety and sleep disturbance in PTSD, but this practice is contraindicated. The short-term symptomatic benefit is outweighed by worse long-term outcomes, increased suicide risk, and interference with evidence-based psychotherapy 6.
If a patient with PTSD is already taking clonazepam, taper slowly to avoid withdrawal seizures 9. Do not stop abruptly.